Table of Contents
1. Executive Summary
- 1.1 Aims of this Report
- 1.2 Chapter Breakdown
2. Neurodegenerative Diseases: An Introduction
- 2.1 What Are Neurodegenerative Diseases?
- 2.2 Prevalence and Economic Impact
- 2.3 Types of Neurodegenerative Diseases
- 2.3.1 Parkinson' s Disease
- 2.3.2 Alzheimer' s Disease
- 2.3.3 Multiple Sclerosis
- 2.3.4 Huntington' s Disease
- 2.3.5 Amyotrophic Lateral Sclerosis
- 2.3.6 Neuropathies
- 2.3.7 Prion Diseases
3. Neurodegenerative Diseases, Global Market 2009-2024
- 3.1 Analysis of the Current Market
- 3.2 Neurodegenerative Diseases, Forecast 2009-2024
- 3.3 Symptomatic Treatment
- 3.4 Multiple Sclerosis at the Forefront of the Market
- 3.5 Future Directions
4. Parkinson' s Disease
- 4.1 Prevalence and Economic Impact
- 4.2 Current Treatment Options
- 4.3 Parkinson' s Disease Market Forecast 2009-2024
- 4.4 Sifrol Forecast 2009-2024
- 4.5 Stalevo Forecast 2009-2024
- 4.5.1 Patent Expiries and Generic Challenges
- 4.5.2 The FIRST STEP trial
- 4.6 ReQuip Forecast 2009-2024
- 4.6.1 Patents and Lifecycle Management
- 4.7 Concluding Remarks
5. Alzheimer' s Disease
- 5.1 Prevalence and Economic Impact
- 5.2 Treatment Options
- 5.3 Analysis of the Current Market
- 5.4 Alzheimer' s Disease Market Forecast 2009-2024
- 5.5 Aricept Forecast 2009-2024
- 5.6 Namenda Forecast 2009-2024
- 5.6.1 Patents and Generic Challenges
- 5.7 Exelon Forecast 2009-2024
- 5.8 Reminyl Forecast 2009-2024
- 5.9 Future Directions and Concluding Remarks
6. Multiple Sclerosis
- 6.1 Economic and Social Impact
- 6.2 Treatment Options
- 6.2.1 Treatment for Relapses
- 6.2.2 Treatment for Symptoms
- 6.2.3 Disease-Modifying Medicines
- 6.3 Analysis of the Current Market
- 6.4 Multiple Sclerosis Market Forecast 2009-2024
- 6.5 Avonex Forecast 2009-2024
- 6.5.1 Markets and Patent Expiries
- 6.5.2 Strong Competition Will Erode Market Share
- 6.6 Copaxone Forecast 2009-2024
- 6.6.1 A Unique Therapy - For Now
- 6.6.2 Forthcoming Patent Expiries
- 6.7 Rebif Forecast 2009-2024
- 6.7.1 New Delivery Mechanism to Improve Sales
- 6.7.2 Efficacy Studies
- 6.8 Betaferon Forecast 2009-2024
- 6.8.1 Patent Expiries
- 6.8.2 Strong Competition
- 6.9 Future Directions
- 6.9.1 The Re-Launch of Tysabri
7. Amyotrophic Lateral Sclerosis
- 7.1 Possible Causes of ALS
- 7.2 Prevalence
- 7.3 Treatment Options
- 7.4 Analysis of the Current Market
- 7.5 Amyotrophic Lateral Sclerosis Market Forecast 2009-2024
- 7.6 Rilutek Forecast 2009-2024
- 7.6.1 New Indications
- 7.6.2 Patents
- 7.7 Future Directions
8. Neuropathies
- 8.1 Treating the Underlying Cause
- 8.2 Surgery and Physical Therapy
- 8.3 Pharmacological Treatments
- 8.3.1 Aldose Reductase Inhibitors
- 8.3.2 Antidepressants
- 8.3.3 Analgesics
- 8.3.4 Anticonvulsants
- 8.4 Analysis of the Current Market
- 8.4.1 Economic and Social Impact
- 8.4.2 Increasing Prevalence and Treatment Strategies
- 8.5 Neuropathies Market Forecast 2009-2024
- 8.6 Kinedak Forecast 2009-2024
- 8.6.1 Adverse Effects and Safety Warnings
- 8.6.2 Direct Competition in the Pipeline
- 8.7 Future Directions
9. Huntington' s Disease
- 9.1 Prevalence and Economic Impact
- 9.2 Treatment Options
- 9.2.1 Monoamine-Depleting Agents
- 9.2.2 Benzodiazepines
- 9.2.3 Dopamine Antagonists
- 9.3 Analysis of the Current Market and Future Directions
10. Prion Diseases
- 10.1 Creuztfeldt-Jacob Disease
- 10.2 Gerstmann-Straussler-Scheinker Disease
- 10.3 Kuru
- 10.4 Fatal Familial Insomnia
- 10.5 Prevalence
- 10.6 Analysis of the Current Market
- 10.6.1 Increasing Prevalence Could Alter the Market
11. Geographical Breakdown of the Market
- 11.1 USA
- 11.2 Europe
- 11.3 Emerging Markets
- 11.3.1 China versus India
- 11.3.2 Brazil
- 11.4 Concluding Remarks
12. Future Directions
- 12.1 Stem Cell Therapy for Neurodegenerative Diseases
- 12.2 Cybrids: "Disease in a Dish" Models
- 12.3 Gene Therapy: Promising Results
- 12.4 Hopes for Alzheimer' s Treatment
- 12.4.1 Monoclonal Antibody Bapineuzumab (AAB-001)
- 12.4.2 Monoclonal Antibody Solanezumab
- 12.5 The MS Pipeline
- 12.5.1 Monoclonal Antibodies for the Treatment of MS
- 12.5.2 Managing Immune Activity
- 12.5.3 Statins: A Further Role?
- 12.5.4 Concluding Remarks on the MS Pipeline
- 12.6 Huntington' s Disease: Future Developments
- 12.6.1 Dimebon
- 12.6.2 Cystamine
- 12.6.3 HDAC Inhibitors
- 12.6.4 RNAi as a Potential Treatment
- 12.6.5 The Case for Brain-Derived Neurotrophic Factor (BDNF)
- 12.6.6 What About Stem Cells and Gene Therapy?
- 12.7 ALS: The Pipeline
- 12.7.1 Knopp Neurosciences' KNS-760704
- 12.7.2 CytRx Corporation' s Arimoclomol
13. Drivers and Restraints
- 13.1 Drivers in the Market
- 13.1.1 The Ageing Population and Increasing Prevalence
- 13.1.2 The MS Market: Oral Products May Expand Revenues
- 13.1.3 Advances in Research
- 13.1.4 Chronic Diseases: Long-Term Repeat Sales
- 13.1.5 Unmet Needs in the Patient Population
- 13.2 Restraints in the Market
- 13.2.1 High Product Competition
- 13.2.2 The High Cost of Treatment
- 13.2.3 The MS Market: Patient Compliance
- 13.2.4 Patent Expiries and Generic Competition
- 13.3 Concluding Remarks
14. Expert Opinions
- 14.1 Interview with Dr Johan Luthman
- 14.1.1 On Understanding the Disease and its Treatments
- 14.1.2 On Unmet Needs for Treatments
- 14.1.3 On Current Treatment Options
- 14.1.4 On Future Treatment Possibilities
- 14.1.5 On Stem Cell Media Coverage
- 14.1.6 On the Therapeutic and Curative Potential of Stem Cells for
Neurological Diseases
- 14.1.7 On the Treatment of Neurological Diseases
- 14.1.8 On the Time Frame for Marketable Stem Cell Treatment Options
- 14.2 Interview with Dr Allan Tobin (CHDI Foundation)
- 14.2.1 On the Possibility of a Cure
- 14.2.2 On the Pipeline for Huntington' s Disease
- 14.2.3 On the Advantages and Disadvantages of Studying Huntington' s
Disease
- 14.2.4 On the Market Value of a Treatment for Huntington' s Disease
- 14.3 Interview with Professor Peter Jenner (Proximagen Neurosciences and
King' s College, University of London)
- 14.3.1 On the Challenges in the Treatment of Parkinson' s Disease
- 14.3.2 On Promising Therapeutics
- 14.3.3 On the Possibility of a Cure
- 14.3.4 On Stem Cells in the Treatment of Parkinson' s Disease
- 14.3.5 On Important Areas of Research
15. Conclusions
- 15.1 Multiple Sclerosis Treatments Lead the Market Area
- 15.2 Chronic Conditions and Treatment Options
- 15.3 Comments on the Global Market
- 15.4 Potential in the Pipeline
- 15.5 Geographical Opportunities
List of Tables
- Table 2.1 Types of Neurodegenerative Diseases
- Table 3.1 Neurodegenerative Diseases Market: World Sales ($m), 2008-2014,
2019 and 2024
- Table 4.1 Parkinson' s Disease Symptoms
- Table 4.2 Key Anti-Parkinson Drugs, World Sales ($m) and Market Share (%),
2008
- Table 4.3 Anti-Parkinson' s Therapeutics World Sales ($m), 2008-2014, 2019
and 2024
- Table 5.1 FDA Approved Alzheimer' s Therapeutics, 2009
- Table 5.2 Key Anti-Alzheimer' s Drugs, World Sales ($m) and Market Share
(%), 2008
- Table 5.3 Anti-Alzheimer' s Disease Therapeutics World Sales ($m),
2008-2014, 2019 and 2024
- Table 6.1 Multiple Sclerosis: Possible Risk Factors
- Table 6.2 Multiple Sclerosis Therapeutics World Sales ($m), 2008-2014,
2019 and 2024
- Table 6.3 Leading MS Drugs, World Market Share (%), 2008, 2014, 2019 and
2024
- Table 7.1 Factors Associated With the Onset of ALS
- Table 7.2 Amyotrophic Lateral Sclerosis Therapeutics World Sales ($m),
2008-2014, 2019 and 2024
- Table 8.1 Apparent Causes for Neuropathy
- Table 8.2 Top-Selling Local Anaesthetics ($m), 2008
- Table 8.3 Key Therapeutics Indicated for Neuropathies, 2009
- Table 8.4 Neuropathies Therapeutics World Sales ($m), 2008-2014, 2019 and
2024
- Table 9.1 Treatment Options for Huntington' s Disease, 2009
- Table 10.1 Number of Suspected CJD and GSS Cases in the UK, 1998-2008
- Table 11.1 The Neurodegenerative Market by Country, Sales ($m), CAGR (%)
and Market Share (%), 2008-2014, 2019 and 2024
- Table 12.1 Number of Pipeline Products by Phase and Disease, 2009
- Table 12.2 Key Products in the MS Pipeline, 2009
- Table 13.1 SWOT Analysis for Neurodegenerative Diseases, 2009
List of Figures
- Figure 3.1 The Neurodegenerative Market World Sales ($m), 2008
- Figure 3.2 Neurodegenerative Diseases Market World Sales ($m), 2008-2024
- Figure 3.3 Neurodegenerative Market by Therapeutic Area, World Sales ($m),
2009, 2014 2019, 2024
- Figure 4.1 Anti-Parkinson' s Therapeutics World Sales ($m), 2008-2024
- Figure 4.2 Anti-Parkinson' s Drugs, World Market Share (%), 2008
- Figure 4.3 Sifrol World Sales ($m), 2008-2024
- Figure 4.4 Stalevo World Sales ($m), 2008-2024
- Figure 4.5 ReQuip World Sales ($m), 2008-2024
- Figure 5.1 Key Anti-Alzheimer' s Drugs, World Market Share (%), 2008
- Figure 5.2 Anti-Alzheimer' s Disease Therapeutics World Sales ($m),
2008-2024
- Figure 5.3 Anti-Alzheimer' s Disease Therapeutics World Sales ($m), 2009,
2014, 2019 and 2024
- Figure 5.4 Aricept World Sales ($m), 2008-2024
- Figure 5.5 Namenda World Sales ($m), 2008-2024
- Figure 5.6 Exelon World Sales ($m), 2008-2024
- Figure 5.7 Reminyl World Sales ($m), 2008-2024
- Figure 6.1 Multiple Sclerosis Therapeutics World Sales ($m), 2008-2024
- Figure 6.2 Key Multiple Sclerosis Therapeutic Products, World Sales ($m),
2008
- Figure 6.3 Avonex World Sales ($m), 2008-2024
- Figure 6.4 Copaxone World Sales ($m), 2008-2024
- Figure 6.5 Rebif World Sales ($m), 2008-2024
- Figure 6.6 Betaferon World Sales ($m), 2008-2024
- Figure 6.7 Leading MS Drugs, World Market Share (%), 2008
- Figure 6.8 Leading MS Drugs, World Market Share (%), 2024
- Figure 6.9 Leading MS Drugs, World Sales ($m), 2008, 2014, 2019, 2024
- Figure 7.1 Amyotrophic Lateral Sclerosis Therapeutics World Sales ($m),
2008-2024
- Figure 7.2 Rilutek World Sales ($m), 2008-2024
- Figure 7.3 Amyotrophic Lateral Sclerosis Therapeutics World Sales ($m),
2009, 2014, 2019 and 2024
- Figure 8.1 Neuropathies Therapeutics World Sales ($m), 2008-2024
- Figure 8.2 Neuropathic Pain and General Neuropathic Therapeutics, World
Market Share (%), 2008
- Figure 8.3 Neuropathic Pain and General Neuropathic Therapeutics, World
Sales ($m), 2009, 2014, 2019 and 2024
- Figure 8.4 Kinedak World Sales ($m), 2008-2024
- Figure 8.5 Kinedak and Other General Neuropathic Products, World Sales
($m), 2008, 2014, 2019 and 2024
- Figure 10.1 Number of Suspected CJD and GSS Cases in the UK, 1998-2008
- Figure 11.1 The Neurodegenerative Market by Country, Sales ($m), 2009,
2014, 2019 and 2024
- Figure 11.2 European Neurodegenerative Market, Sales ($m), 2009, 2014,
2019 and 2024
- Figure 11.3 China, India and Brazil, Sales ($m), 2009, 2014, 2019 and 2024
- Figure 11.4 Geographical Breakdown of the World Market, Sales ($m), 2008
- Figure 11.5 Geographical Breakdown of the World Market, Sales ($m), 2024
- Figure 12.1 Number of Pipeline Products by Phase and Disease, 2009
- Figure 12.2 Number of Products in the Alzheimer' s Pipeline by Phase, 2009
Companies Listed
- Acorda Therapeutics
- Active Biotech
- Aguettant
- AstraZeneca
- Bayer
- Biogen Idec
- BioMS Medical
- Boehringer Ingelheim
- Cobalt
- CHDI Foundation
- CytRx Corporation
- Dainippon Sumitomo
- Dr. Reddy' s Laboratories
- Eisai
- Elan
- Eli Lilly
- EMD Serono
- EMEA
- Endo
- Forest
- GlaxoSmithKline
- Hermes
- Insmed
- InterMune
- Johnson & Johnson
- Knopp Neurosciences
- Lundbeck
- Lupin
- Medivation
- Merck & Co
- Merck Serono
- Merck KGaA
- Momenta Pharmaceuticals
- Mylan
- Natco
- Neuren
- Novartis
- Ono Pharmaceuticals
- Orchid
- Orion Corporation
- Pfizer
- Proximagen Neurosciences
- ReceptoPharm
- Roche
- Roxane
- Sanofi-Aventis
- Sun Pharmaceuticals
- Takeda
- Teva
- The Alzheimer' s Association
- The European Medicines Agency
- The Human Fertilisation and Embryology Authority
- The National Academy of Sciences
- The World Health Organisation (WHO)
- Upsher-Smith
- US Food and Drug Administration (FDA)
- Watson Pharmaceuticals
- Wockhardt
- Wyeth
|
Related Report
|
View Cart
